drugset / Trial / NCT02882893

Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines

NCT02882893

Phase 2/3 Unknown 238 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Efficacy and Safety of DWP450 treatment of Crows Feet Lines(CFL).

Timeline

Start
2016-08
Primary completion
2017-01
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic

Indications

No indication recorded.